VALLEY COTTAGE, New York, August 15 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and hepatitis C, today announced its financial results for the six months ended June 30, 2007.
At June 30, 2007, the Company had cash, cash equivalents and short-term bank deposits of $12.6 million, compared to $25.2 million at December 31, 2006. The decrease of $12.6 million during the first six months of 2007 was attributable primarily to the Company's $7.5 million upfront payment made in connection with the in-licensing of Bicifadine in January 2007, operating expenditures associated with the planned Phase IIb clinical trial of Bicifadine, the development of the DOS hepatitis C pre-clinical program, and operating expenditures associated with the Company's legacy hepatitis C clinical programs that were terminated this year.
The loss for the six months ended June 30, 2007 was $14.6 million, or
$0.07 per ordinary share, compared to a loss of $7.3 million, or $0.04 per
ordinary share, for the six months ended June 30, 2006, representing an
increase in net loss of $7.3 million. The increased loss was primarily
attributable to the $7.5 million upfront payment in connection with the
in-licensing of Bicifadine and additional costs associated with the
Bicifadine program, offset by lower costs associated with the Company's
legacy hepatitis C clinical programs. The increase in loss was also due to
a $0.6 million charge that was recorded relating to stock appreciation
rights granted as part of the Bicifadine transac
|SOURCE XTL Biopharmaceuticals Ltd|
Copyright©2007 PR Newswire.